News Spotlight: AstraZeneca (LSE/STO/NYSE:AZN)

AstraZeneca (NYSE:AZN) stock identified change of 26.80% away from 52-week low price and recently located move of -2.04% off 52-week high price. It has market worth of $117054.11M and dividend yield of 3.13%. AZN stock has been recorded 4.36% away from 50 day moving average and 11.54% away from 200 day moving average. Moving closer, we can see that shares have been trading 0.09% off 20-day moving average.

On Sept. 05, 2019,  Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, declared a licence agreement with AstraZeneca (LSE/STO/NYSE:AZN) for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi (Poly (ADP-Ribose) Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi. 

PARP inhibitors are a novel class of oncology drugs that block an enzyme, Poly (ADP-Ribose) Polymerase, that cancer cells use in response to DNA damage, both endogenous and as caused by treatments such as chemotherapy.

Theragnostics’ technology platform enables the development of molecular radiotherapy based on a PARPi for imaging and treating cancer. Theragnostics modifies a PARPi drug molecule with a radioactive atom to create a radionuclide PARPi (rPARPi). This can either be used to image PARP in a cancer patient for diagnostic use or the radioactive isotope can be used to deliver a therapeutic dose of radiation into tumour cells, which offers the potential to molecularly target the radiation in order to hit and kill tumour cells whilst avoiding damage to healthy cells and associated side effects.

The potential market for PARP inhibitors is large. There are at least four approved conventional pharmaceutical PARPi on the market with new and expanded indications being approved in several markets in recent months, opening up a multibillion-dollar opportunity. Analysts estimate that peak sales for the PARPi class could reach $4.8 billion by 2023 (source, Evaluate Pharma), a figure which only includes indications in ovarian, breast and prostate cancer. Analyst PARPi peak sales forecasts could rise as newer indications and label expansions are included within estimates. PARPi is a therapeutic class that could be applicable in up to 40% of tumours with varying DNA Damage Response associated mutations or dependencies and may have additional efficacy in combination with chemotherapy or radiotherapy.

 The Healthcare sector company, AstraZeneca PLC noticed change of -1.28% to $44.76 along volume of 1606836 shares in recent session compared to an average volume of 2929.07K. The stock observed return of -0.09% in 5 days trading activity. The stock was at 2.61% over one month performance. AZN’s shares are at 15.27% for the quarter and driving a 18.35% return over the course of the past year and is now at 17.85% since this point in 2018. 

 The average volatility for the week at 0.87% and for month was at 1.16%. There are 2615.15M shares outstanding and 2614.93M shares are floated in market. Right now the stock beta is 0.47. 

Leave a Reply

Your email address will not be published. Required fields are marked *